Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK

被引：0
|
作者：
Johnston, K. [1 ]
Powell, L. [1 ]
Popoff, E. [1 ]
L'Italien, G. [2 ]
Pawinski, R. [3 ]
Ahern, A. [3 ]
Large, S. [3 ]
Tran, T. [4 ]
Jenkins, A. [3 ]
机构：
[1] Broadst Hlth Econ & Outcomes Res, Vancouver, BC, Canada
[2] Biohaven Pharmaceut Inc, New Haven, CT USA
[3] Pfizer Ltd, Tadworth, England
[4] Pfizer Canada, Kirkland, PQ, Canada
来源：
JOURNAL OF HEADACHE AND PAIN | 2024年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P038
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Spain
    Maroto, P.
    Villavicencio, H.
    Pinol, C.
    Urruticoechea, L.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A280
  • [32] Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma.
    Gao, X.
    Reddy, P.
    Dhanda, R.
    Gondek, K.
    Yeh, Y. C.
    Stadler, W. M.
    Jonasch, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
  • [33] Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
    Goswami, Hardik
    Alsumali, Adnan
    Jiang, Yiling
    Schindler, Matthias
    Duke, Elizabeth R.
    Cohen, Joshua
    Briggs, Andrew
    Puenpatom, Amy
    PHARMACOECONOMICS, 2022, 40 (07) : 699 - 714
  • [34] COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS IN COMPARISON WITH BEST SUPPORTIVE CARE IN IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY
    Erdogan-Ciftci, E.
    Yanik, L.
    Ersoy, Akyol B.
    Safak, K.
    Thuresson, P. O.
    VALUE IN HEALTH, 2019, 22 : S849 - S849
  • [35] Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
    Hardik Goswami
    Adnan Alsumali
    Yiling Jiang
    Matthias Schindler
    Elizabeth R. Duke
    Joshua Cohen
    Andrew Briggs
    Amy Puenpatom
    PharmacoEconomics, 2022, 40 : 699 - 714
  • [36] Cost-effectiveness of etoricoxib compared to traditional NSAIDs in the UK
    Moore, A
    Phillips, C
    Hunsche, E
    Pellissier, J
    Kingslake, S
    Kong, SX
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 354 - 354
  • [37] Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine
    Ailani, Jessica
    Gandhi, Pranav
    Lalla, Anjana
    Singh, Rashmi Halker
    McAllister, Peter
    Smith, Jonathan H.
    Dabruzzo, Brett
    Chalermpalanupap, Natty
    Kelton, Kari
    Nahas, Stephanie J.
    HEADACHE, 2024, 64 (10): : 1253 - 1263
  • [38] Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine
    Zhang, L
    Hay, JW
    VALUE IN HEALTH, 2004, 7 (03) : 289 - 289
  • [39] Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot® in the acute treatment of migraine
    Zhang, LH
    Hay, JW
    CNS DRUGS, 2005, 19 (07) : 635 - 642
  • [40] Cost-Effectiveness Analysis of Rizatriptan and Sumatriptan versus Cafergot® in the Acute Treatment of Migraine
    Lihua Zhang
    Joel W. Hay
    CNS Drugs, 2005, 19 : 635 - 642
12345